CD2 Antibody (12-15) [FITC]

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-26667

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP1-26667
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Validated:

Mouse

Applications

Flow Cytometry

Label

FITC (Excitation = 495 nm, Emission = 519 nm)

Antibody Source

Monoclonal Rat IgG1 kappa Clone # 12-15

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all CD2 Antibodies »

Product Summary for CD2 Antibody (12-15) [FITC]

Immunogen

Crude plasma membranes of ESb cells

Specificity

Mouse CD2/LFA-2 (Mr 45-58 kDa)

Clonality

Monoclonal

Host

Rat

Isotype

IgG1 kappa

Scientific Data Images for CD2 Antibody (12-15) [FITC]

Flow Cytometry: CD2 Antibody (12-15) [FITC] [NBP1-26667] - 1 ug/1^6 BALB/c lymph node cells were stained with rat anti-mouse CD2-FITC. Lymphocytes were then gated and analyzed by flow cytometry.
Flow Cytometry: CD2 Antibody (12-15) [FITC] [NBP1-26667] - C57BL/6 mouse splenocytes stained with NBP1-26669 (PE conjugate) and NBP1-26667 (FITC conjugate)

Applications for CD2 Antibody (12-15) [FITC]

Application
Recommended Usage

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C. Do not freeze.

Background: CD2

CD2, also known as sheep red blood cell receptor (SRBC-R), erythrocyte receptor, LFA-2, and T11, is a type I transmembrane glycoprotein that is expressed on the surface of T cells, natural killer (NK) cells, thymocytes, and dendritic cells (1,2). CD2 is a member of the immunoglobulin (Ig) superfamily and a costimulatory receptor that functions in formation of the immunological synapse and T cell activation and signaling (1). The human CD2 protein is 351 amino acids in length with a theoretical molecular weight of ~40 kDa, but a fully glycosylated protein can weight closer to 50 kDa (1,3). The CD2 protein contains a signal sequence, an extracellular domain (ECD) composed of an Ig-like V-type domain followed by an Ig-like C-type domain, a transmembrane helical domain, and a proline-rich cytoplasmic tail (1,3). CD2 binds with CD58, also called LFA-3, which is a surface glycoprotein expressed by antigen presenting cells (APCs) and other target cells (1,2). While CD58 is the primary ligand for CD2 in humans, it also interacts with CD59 and CD48, albeit with lower affinity (1,2). However, in mice and rats which lack CD58 the main ligand for CD2 is CD48 (4). Research has found that when there is no direct interaction, CD2 co-immunoprecipitates with the T cell receptor (TCR)/CD3 complex (1). CD2 is an adhesion molecule with a variety of functions including actin cytoskeleton rearrangement, immunological synapse formation through T cell-APC binding, thymocyte development and T cell activation, and NK cell activation (1,2). The immunological synapse forms upon T cell-APC engagement and creates a contact zone of supramolecule activation clusters (SMACs) where CD2-CD58 is part of the central SMAC (cSMAC) (2).

The CD2-CD58 interaction has been shown to play a role in anti-tumor immune response, where reduced CD58 signaling is associated with immune escape of tumor cells in various hematological and lymphoid malignancies, but restoration of the signal promotes an anti-tumor response (2,5). Additionally, following cytomegalovirus (CMV) infection, CD2's binding to upregulated CD58 on CMV-infected cells is crucial for the activation and function of adaptive NK cells in the anti-viral response (2). In contrast, in situations where there is an increase in T cell and NK cell activation, like various autoimmune disorders or following organ transplant, costimulatory blockade of CD2-CD58 may be a potential therapeutic treatment approach (1). Mouse and rat xenograft models have shown that blocking the CD2 using anti-CD2 monoclonal antibodies contributes to graft survival and protects against lymphocyte infiltration and inflammatory damage (2).

References

1. Binder C, Cvetkovski F, Sellberg F, et al. CD2 Immunobiology. Front Immunol. 2020;11:1090. https://doi.org/10.3389/fimmu.2020.01090

2. Zhang Y, Liu Q, Yang S, Liao Q. CD58 Immunobiology at a Glance. Front Immunol. 2021;12:705260. https://doi.org/10.3389/fimmu.2021.705260

3. Uniprot (P06729)

4. van der Merwe PA. A subtle role for CD2 in T cell antigen recognition. J Exp Med. 1999;190(10):1371-1374. https://doi.org/10.1084/jem.190.10.1371

5. Nishikori M, Kitawaki T, Tashima M, Shimazu Y, Mori M, et al. Diminished CD2 Expression in T cells Permits Tumor Immune Escape. J Clin Cell Immunol. 2016;7:406. https://doi.org/10.4172/2155-9899.1000406

Alternate Names

CD2, LFA-2, T11

Gene Symbol

CD2

Additional CD2 Products

Product Documents for CD2 Antibody (12-15) [FITC]

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for CD2 Antibody (12-15) [FITC]

Protect conjugated forms from light.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.